Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: Comparison with CT and PET

Journal of Clinical Oncology

Volumn 22, Issue 21, 2004, Pages 4357-4368

  Antoch, Gerald ^a   Saoudi, Nina ^a   Kuehl, Hilmar ^a   Dahmen, Gerlinde ^a   Mueller, Stefan P ^a   Beyer, Thomas ^a   Bockisch, Andreas ^a   Debatin, Jörg F ^a   Freudenberg, Lutz S ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TREATMENT PLANNING; ADOLESCENT; ADULT; AGED; FEMALE; MALE; METHODOLOGY; MIDDLE AGED; NEOPLASM; PREDICTION AND FORECASTING; RADIOGRAPHY; SCINTISCANNING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 16544379070     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.08.120     Document Type: Article

References (38)

1. Smythe WR: Treatment of stage I and II non-small-cell lung cancer. Cancer Control 8:318-325, 2001
2. Cerny T, Giaccone G: Pleura mesothelioma: Combined modality treatments. Ann Oncol 13:217-225. 2002 (suppl 4)
3. Cerny T, Gillessen S: Advances in the treatment of non-Hodgkin's lymphoma. Ann Oncol 13:211-216, 2002 (suppl 4)
4. Forastiere A, Koch W, Trotti A, et al: Head and neck cancer. N Engl J Med 345:1890-1900, 2001
5. Haberkorn U, Schoenberg SO: Imaging of lung cancer with CT, MRT and PET. Lung Cancer 34:S13-S23, 2001 (suppl 3)
6. Toloza EM, Harpole L, McCrory DC: Noninvasive staging of non-small cell lung cancer: A review of the current evidence. Chest 123:137S-146S, 2003
7. Adams S, Baum RP, Stuckensen T, et al: Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer. Eur J Nucl Med 25:1255-1260, 1998
8. Marom EM, McAdams HP, Erasmus JJ, et al: Staging non-small cell lung cancer with whole-body PET. Radiology 212:803-809, 1999
9. van Tinteren H, Hoekstra OS, Smit EF, et al: Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: The PLUS multicentre randomised trial. Lancet 359: 1388-1393, 2002
10. Diederichs CG, Staib L, Vogel J, et al: Values and limitations of 18F-fluorodeoxyglucose-positron-emission tomography with preoperative evaluation of patients with pancreatic masses. Pancreas 20:109-116, 2000
11. Weber WA, Avril N, Schwaiger M: Relevance of positron emission tomography (PET) in oncology. Strahlenther Onkol 175:356-373, 1999
12. Wahl RL, Quint LE, Cieslak RD, et al: "Anatometabolic" tumor imaging: Fusion of FDG PET with CT or MRI to localize foci of increased activity. J Nucl Med 34:1190-1197, 1993
13. Townsend DW: A combined PET/CT scanner: The choices. J Nucl Med 42:533-534, 2001
14. Beyer T, Townsend DW, Blodgett TM: Dual-modality PET/CT tomography for clinical oncology. Q J Nucl Med 46:24-34, 2002
15. Hany TF, Steinert HC, Goerres GW, et al: PET diagnostic accuracy: Improvement with in-line PET-CT system-Initial results. Radiology 225:575-581, 2002
16. Lardinois D, Weder W, Hany TF, et al: Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 348:2500-2507, 2003
17. Antoch G, Vogt FM, Freudenberg LS, et al: Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. JAMA 290:3199-3206, 2003
18. Antoch G, Stattaus J, Nemat AT, et al: Non-small cell lung cancer: Dual-modality PET/CT in preoperative staging. Radiology 229: 526-533, 2003
19. Bossuyt PM, Reitsma JB, Bruns DE. et al: Towards complete and accurate reporting of studies of diagnostic accuracy: The STARD initiative. Clin Radiol 58:575-580, 2003
20. Beyer T, Antoch G, Blodgett T, et al: Dual-modality PET/CT imaging: The effect of respiratory motion on combined image quality in clinical oncology. Eur J Nucl Med Mol Imaging 30:588-596, 2003
21. Kinahan PE, Townsend DW, Beyer T. et al: Attenuation correction for a combined 3D PET/CT scanner. Med Phys 25:2046-2053, 1998
22. Beggs AD, Hain SF, Curran KM, et al: FDG-PET as a "metabolic biopsy" tool in non-lung lesions with indeterminate biopsy. Eur J Nucl Med Mol Imaging 29:542-546, 2002
23. Patz EF Jr. Lowe VJ, Hoffman JM, et al: Focal pulmonary abnormalities: Evaluation with F-18 fluorodeoxyglucose PET scanning. Radiology 188:487-490, 1993
24. AJCC: AJCC Cancer Staging Manual (ed 6). New York, NY, Springer, 2002
25. National Coverage Determinations: Positron Emission Tomography (PET) Scans, Centers for Medicare and Medicaid Services. http://cms.hhs.gov/mcd/ viewdecisionmemo.asp ?id=85
26. Germany AotSMSi: Guidelines for Stage-Adapted Tumor Therapy. 2003. http://www .awmf-online.de
27. Thoeni RF: Colorectal cancer: Radiologic staging. Radiol Clin North Am 35:457-485, 1997
28. Vansteenkiste JF, Stroobants SG, De Leyn PR, et al: Lymph node staging in non-small-cell lung cancer with FDG-PET scan: A prospective study on 690 lymph node stations from 68 patients. J Clin Oncol 16:2142-2149, 1998
29. Pieterman RM, van Putten JW, Meuzelaar JJ, et al: Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med 343:254-261, 2000
30. Deslauriers J, Gregoire J: Clinical and surgical staging of non-small cell lung cancer. Chest 117:96S-103S, 2000 (suppl 1)
31. Staples CA, Muller NL, Miller RR, et al: Mediastinal nodes in bronchogenic carcinoma: Comparison between CT and mediastinoscopy. Radiology 167:367-372, 1988
32. Gambhir SS, Czernin J, Schwimmer J, et al: A tabulated summary of the FDG PET literature. J Nucl Med 42:1S-93S, 2001
33. Antoch G, Freudenberg LS, Egelhof T, et al: Focal tracer uptake: A potential artifact in contrast-enhanced dual- modality PET/CT scans. J Nucl Med 43:1339-1342, 2002
34. Antoch G, Jentzen W, Freudenberg LS, et al: Effect of oral contrast agents on computed tomography-based positron emission tomography attenuation correction in dual-modality positron emission tomography/computed tomography imaging. Invest Radiol 38:784-789, 2003
35. Antoch G, Freudenberg LS, Beyer T, et al: To enhance or not to enhance? (18)F-FDG and CT contrast agents in dual-modality (18)F-FDG PET/CT. J Nucl Med 45:56S-65S, 2004 (suppl 1)
36. Dizendorf E, Many TF, Buck A, et al: Cause and magnitude of the error induced by oral CT contrast agent in CT-based attenuation correction of PET emission studies. J Nucl Med 44: 732-738, 2003
37. Cohade C, Osman M, Nakamoto Y, et al: Initial experience with oral contrast in PET/CT: Phantom and clinical studies. J Nucl Med 44: 412-416, 2003
38. Beyer T, Antoch G, Kuehl H, et al: Acquisition schemes for combined 18F-FDG PET/CT imaging: A European experience, in Czernin J, Dahlbom M, Ratib O, et al (eds): Atlas of PET/CT Imaging in Oncology. New York, Springer, 2004, pp 30-45